NIOX Group Plc (CSSPF)

0.7500 0.0000 (0.00%) At close: 10:31AM EDT

NIOX Group Plc

Hayakawa Building
Edmund Halley Road The Oxford Science Park
Oxford OX4 4GB
United Kingdom
44 3303 309 356
https://investors.niox.com

Sector(s): Healthcare
Industry: Medical Devices
Full-time employees: 92

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Ian Roy Johnson	Executive Chairman	814.3k	N/A	1953
Mr. Michael Roy David Roller A.C.A., BA (Hons)	CFO & Director	636.13k	N/A	1965
Mr. Jonathan Emms	COO & Executive Director	818.06k	N/A	1963
Ms. Nina Kataria	Senior Vice President Global Human Resources	N/A	N/A	N/A
Mr. Tom Scaccia	Senior Vice President of Americas & Research Business	N/A	N/A	N/A
Ms. Sarah Elizabeth Duncan	Company Secretary	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

NIOX Group Plc engages in the design, development, and commercialization of medical devices for the measurement of fractional exhaled nitric oxide (FeNo) worldwide. Its products include NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device and a range of consumables, including sensors, individual disposable mouthpieces, and breathing handles for the measurement of FeNo level in patients. The company was formerly known as Circassia Group Plc and changed its name to NIOX Group Plc in September 2022. NIOX Group Plc was incorporated in 2006 and is headquartered in Oxford, the United Kingdom.

Corporate governance

NIOX Group Plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.